Medically authored by Dr. Mario Quiros, MD — Board-Certified Emergency Medicine & Obesity Medicine Physician | Good Hearts Health
GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed the treatment of type 2 diabetes and obesity. But as millions of patients now use these medications, reports of skin hypersensitivity reactions are drawing increased attention from clinicians and patients alike.
If you are experiencing a rash, hives, or injection site irritation while on a GLP-1 medication, this guide covers everything you need to know.
What Are Skin Hypersensitivity Reactions?
Skin hypersensitivity reactions are immune-mediated responses in which the body overreacts to a substance — in this case, a GLP-1 receptor agonist or one of its inactive ingredients. These reactions range from mild localized irritation to rare but serious systemic allergic responses.
They are distinct from simple side effects like nausea or diarrhea. Skin reactions involve the immune system and can evolve unpredictably, which is why early recognition matters.
What Causes Skin Hypersensitivity Reactions in GLP-1 Medications?
Several mechanisms can trigger skin reactions in patients taking GLP-1 medications:
1. Injection Site Reactions
The most common skin reaction, affecting an estimated 5–20% of patients. Localized redness, swelling, itching, bruising, or nodule formation at the injection site can result from the needle puncturing subcutaneous tissue repeatedly in the same location, the pH or osmolality of the drug formulation irritating local tissue, or a localized immune response to the peptide or excipients.
2. IgE-Mediated (Type I) Hypersensitivity
This is a true allergic reaction where the immune system produces IgE antibodies against the drug or its components. It can manifest as urticaria (hives), angioedema (swelling of deeper tissue layers), or — in rare cases — anaphylaxis. Symptoms typically occur within minutes to hours of administration.
3. Delayed (Type IV) Hypersensitivity
A T-cell-mediated reaction that develops 24–72 hours after exposure. This typically presents as a contact-dermatitis-like rash at or around the injection site and may worsen with repeated exposure.
4. Bullous Pemphigoid
A rare but serious skin condition linked to certain GLP-1 agents. It causes large, fluid-filled blisters on the skin due to autoantibodies attacking the skin’s basement membrane. The exact mechanism is still under investigation, but immunomodulatory effects of the drug class are suspected.
5. Lipodystrophy
Repeated injections in the same site can cause lipoatrophy (loss of fat) or lipohypertrophy (excess fat buildup), altering skin texture and drug absorption. While not a traditional allergic reaction, it reflects a localized tissue response to repetitive mechanical and chemical injury.
How Common Are These Reactions?
Injection site reactions (mild) occur in an estimated 5–20% of patients. Urticaria or generalized rash affects 1–5%. Angioedema occurs in under 1%. Bullous pemphigoid is rare, based on case reports and emerging data. Anaphylaxis is very rare (under 0.1%), and DRESS is very rare as well.
Mild injection site reactions are by far the most common and typically resolve on their own. Serious systemic reactions are uncommon but require immediate medical attention.
Are GLP-1 Skin Reactions Dangerous?
Most are not. The majority of patients who experience skin reactions have mild, localized symptoms that improve without medical intervention or with simple management strategies.
However, certain reactions warrant urgent care. Seek emergency care immediately if you notice: throat tightening, difficulty breathing, or wheezing (signs of anaphylaxis); rapid spread of hives across the body combined with dizziness or a drop in blood pressure; widespread blistering of the skin; or fever, facial swelling, or internal organ symptoms alongside a rash (possible DRESS).
Bullous pemphigoid, while not immediately life-threatening, can be debilitating and requires prompt dermatological evaluation. If left untreated, blistering can lead to secondary infections and significant morbidity — particularly in older adults.
How Are GLP-1 Skin Hypersensitivity Reactions Treated?
Mild Injection Site Reactions
Rotate injection sites (abdomen, thigh, upper arm) with each dose. Apply a cool compress after injecting. Use over-the-counter topical hydrocortisone cream to reduce localized inflammation. Oral antihistamines (e.g., cetirizine, loratadine) can relieve itching.
Urticaria and Generalized Rash
Oral antihistamines are first-line treatment. If symptoms persist, a short course of oral corticosteroids may be prescribed. Depending on severity, the prescribing clinician may pause or switch the GLP-1 medication.
Angioedema
Mild angioedema without airway involvement: antihistamines and monitoring. Severe angioedema or any airway compromise: epinephrine (EpiPen), emergency care, and discontinuation of the drug.
Anaphylaxis
Immediate epinephrine injection (IM, lateral thigh), emergency transport, permanent discontinuation of the offending GLP-1 agent, and allergy/immunology evaluation for potential cross-reactivity with other agents in the class.
Bullous Pemphigoid
Dermatology referral is essential. Topical or systemic corticosteroids are the cornerstone of treatment. Immunosuppressants (e.g., dapsone, azathioprine, methotrexate) may be used in refractory cases. The GLP-1 medication is typically discontinued, though the decision should be weighed against the patient’s metabolic needs.
How to Prevent Skin Hypersensitivity Reactions on GLP-1 Medications
Before Starting Treatment
- Disclose your full allergy history to your prescribing clinician, including reactions to other injectable medications or peptide-based drugs.
- Review excipient ingredients in the specific formulation — some patients react to inactive ingredients like polysorbate 80 or metacresol rather than the active peptide itself.
- Start with a supervised first injection if there is any concern about hypersensitivity history.
Injection Technique
- Rotate sites systematically — never inject the same spot twice in a row; use a rotation chart if needed.
- Allow the pen or syringe to reach room temperature before injecting (10–15 minutes out of the refrigerator) to reduce local irritation.
- Pinch the skin gently and inject at the correct angle to ensure subcutaneous — not intramuscular — delivery.
- Do not inject into areas of active irritation, redness, bruising, or lipodystrophy.
Ongoing Monitoring
- Inspect injection sites after every dose for early signs of reaction.
- Keep a symptom log for the first 8–12 weeks of treatment, noting any skin changes, their timing relative to injections, and their location.
- Communicate promptly with your healthcare provider about any new or worsening skin symptoms — do not wait until the next scheduled appointment.
For Patients with a Previous Mild Reaction
- A clinician may recommend premedication with an antihistamine 30–60 minutes before each injection.
- Switching to a different GLP-1 agent with a different formulation may eliminate the reaction if the trigger is an excipient rather than the peptide class itself.
- Desensitization protocols are experimental and not standard of care, but may be considered in specialist settings for patients with significant metabolic benefit from the drug.
When Should You Stop Taking a GLP-1 Medication?
Stop the medication and contact your provider if you experience a rash that is rapidly spreading, blistering, or involving mucous membranes; any symptoms of anaphylaxis (airway involvement, hypotension, loss of consciousness); widespread blistering suggestive of bullous pemphigoid; or a rash accompanied by fever, facial swelling, or lymph node enlargement.
For mild injection site reactions alone, you do not need to stop the medication — site rotation and topical care are usually sufficient. Injection site reactions often resolve on their own a few weeks after they initially appear. I typically do not recommend discontinuing the medication for mild, localized injection site reactions unless they are causing a patient distress due to persistent itching or irritation. Any side effects should be reported to the physician prescribing you the medication and decisions to discontinue medication should only be made after notifying your physician.
The Bottom Line
Skin hypersensitivity reactions to GLP-1 medications are real but, in the vast majority of cases, manageable. Mild injection site reactions are common and rarely require stopping treatment. Serious systemic reactions — while medically significant — are uncommon.
The key is awareness: patients and clinicians who know what to watch for can catch reactions early, respond appropriately, and make informed decisions about whether to continue, modify, or discontinue treatment. Given the substantial cardiometabolic benefits of GLP-1 medications, the goal is always to keep patients on therapy safely whenever possible.
Frequently Asked Questions
Q: Can I switch to a different GLP-1 medication if I have a skin reaction?
Yes, in many cases. If the reaction is caused by an excipient rather than the GLP-1 peptide itself, switching formulations may resolve it. However, if the reaction is to the peptide class broadly, cross-reactivity is possible. An allergist can help assess this.
Q: Do you see a higher incidence of Skin Reactions with Tirzepatide compared to Semaglutide?
Yes, localized skin reactions are much more common with Tirzepatide compared to Semaglutide. While Tirzepatide is a more effective drug in terms of weight loss and generally has a more favorable side effect profile, I do see an increased incidence of localized skin reactions in patients taking Tirzepatide compared to patients taking Semaglutide.
Q: How long do injection site reactions typically last?
Most resolve within a few hours to days. If a reaction persists beyond a week or worsens, contact your provider.
Q: Can GLP-1 medications cause eczema to flare?
There is limited evidence that GLP-1 agents directly trigger eczema flares, but the immune modulation and skin barrier disruption at injection sites may worsen pre-existing atopic conditions in some patients.
Q: Is bullous pemphigoid permanent?
Not always. In drug-induced cases, discontinuing the offending medication often leads to remission, though treatment is still required while the blistering is active.
Q: Should I carry an EpiPen if I’m on a GLP-1 medication?
Not routinely. Your clinician will advise you on whether your personal risk profile warrants a prescribed epinephrine auto-injector.
Q: Where can I book a consultation with a board certified Obesity Medicine physician and see if GLP-1 therapy for weight loss may be right for me?
You can visit our website and book a free consultation to see if our concierge weight loss program is right for you.
References & Further Reading
- FDA Prescribing Information: Ozempic (Semaglutide) — Hypersensitivity & Adverse Reactions
- Burke et al. (2025). Dermatologic Implications of GLP-1 Receptor Agonist Medications. Skin Appendage Disorders. Karger Publishers.
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons. PMC/NIH.
- Tirzepatide in Dermatology: Cutaneous Adverse Events, Emerging Therapeutic Roles, and Cosmetic Implications — A Comprehensive Review. PMC/NIH.
- Semaglutide-Associated Bullous Pemphigoid. PMC/NIH.
- Examining the Association of GLP1-RA or DPP4i with Bullous Skin Diseases in Veterans. Journal of the Endocrine Society. Oxford Academic.
- Identifying Potential Drug Triggers for Bullous Pemphigoid: A Disproportionality Analysis of the FDA Adverse Event Reporting System. Cutaneous and Ocular Toxicology.
- Desensitization to Tirzepatide After Recurrent Maculopapular Eruptions to GLP-1 Agonists. Annals of Allergy, Asthma & Immunology.
- A Case Report of Systemic Allergic Reaction to the Dual GIP/GLP-1 Receptor Agonist Tirzepatide. PMC/NIH.
- Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series. American Journal of Case Reports.
- GLP-1 Agonists Associated With Rare Cutaneous Adverse Reactions. Dermatology Advisor.
Ready to Start a Physician-Supervised GLP-1 Weight Loss Program?
At Good Hearts Health, Dr. Mario Quiros provides personalized, board-certified concierge weight loss care using FDA-approved Semaglutide and Tirzepatide therapy. If you are considering GLP-1 therapy and want to do so safely — with proper medical oversight and monitoring for reactions like those described above — we are here to help.
Book your free consultation with Good Hearts Health today →
Medically Authored by Dr. Mario Quiros, MD. Board-Certified Emergency Medicine and Obesity Medicine Physician. Owner and Operator of Good Hearts Health.
